A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies
Sponsor: Aronex Pharmaceuticals
Listed as NCT00057395, this PHASE1/PHASE2 trial focuses on Colorectal Neoplasms and Esophageal Neoplasms and remains ongoing. Sponsored by Aronex Pharmaceuticals, it has been updated 5 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Aronex Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .